LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Product Name Liraglutide Injection

6 mg/ml

Manufacturer Lupin Limited

Nagpur - 441108 Maharashtra, India

Manufactured for Lupin Pharmaceuticals, Inc.

Naples, FL 34108 United States

Use of the Substance/mixture Pharmaceuticals

Section 2: Hazard(s) Identification

Health Please refer to the product information insert.

May be harmful if swallowed.

May cause an allergic skin reaction.

May cause allergy or asthma symptoms or breathing difficulty if inhaled.

Physical Hazard Obtain special instructions before use

Fire and Explosion Expected to be non-combustible

Section 3: Composition/Information on Ingredients

Ingredients	CAS No.	
Liraglutide	204656-20-2	
Propylene Glycol USP	57-55-6	
Disodium Hydrogen Phosphate Dihydrated USP	10028-24-7	
Phenol USP	108-95-2	
Sodium Hydroxide	1310-73-2	
Hydrochloric acid	7647-01-0	
Water for Injection USP	7732-18-5	
Nitrogen gas	7727-37-9	

^{*}The exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: First-Aid Measures

General advice Consult a physician. Show this safety data sheet to the doctor in

attendance.

Eye contact Wash out immediately with water.

If irritation continues, seek medical attention.

Removal of contact lenses after an eye injury should only be undertaken

by skilled personnel.

Skin Contact If skin or hair contact occurs:

Immediately remove all contaminated clothing, including footwear Flush skin and hair with running water (and soap if available).

Seek medical attention in event of irritation.

SDS : 285/00 Page 1 of 5

Inhalation If fumes, aerosols or combustion product are inhale remove from

contaminated areas. Other measures are usually unnecessary.

Ingestion Immediately give a glass of water.

First aid is not generally required. If in doubt, contact a Poisons Information

Centre or a doctor.

Treat symptomatically. Note to physicians

Section 5: Fire-Fighting Measures

Suitable extinguishing media Alert the Fire Brigade and tell them the location and nature of the hazard.

> Prevent, by any means available, spillage from entering drains or water courses. Use water delivered as a fine spray to control the fire and cool the

adjacent area.

Advice for firefighters Positive-pressure self-contained breathing apparatus (SCBA) and structural

firefighters' protective clothing will provide adequate protection

Hazardous combustion products During combustion, it may emit irritant fumes.

Section 6: Accidental Release Measures

Personal precautions, protective equipment, and emergency

procedures

Environmental precautions

Methods and materials for containment and cleaning up Wear suitable protective clothing, gloves, and eye/face protection.

Avoid discharge into drains, water courses, or onto the ground.

Contain the source of the spill if it is safe to do so. Do not touch or walk through spilled material. Absorb spillage to prevent material damage.

Disposal Methods Dispose of in accordance with local, state, and national regulations.

Section 7: Handling and Storage

Precautions for safe handling

Avoid inhalation, contact with eyes, and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.

Advice on safe handling

Handle in accordance with good industrial hygiene and safety practices.

Conditions for safe storage, including any incompatibilities

Storage conditions

Prior to first use, liraglutide injection should be stored in a refrigerator between 36°F to 46°F (2°C to 8°C). Do not store in the freezer or directly adjacent to the refrigerator cooling element.

Do not freeze liraglutide injection, and do not use liraglutide injection if it has been frozen.

After first use of the liraglutide injection pen, the pen can be stored for 30 days at controlled room temperature (59°F to 86°F; 15°C to 30°C) or in a refrigerator (36°F to 46°F; 2°C to 8°C).

Keep the pen cap on when not in use.

Protect liraglutide injection from excessive heat and sunlight.

Always remove and safely discard the needle after each injection and store the liraglutide injection pen without an injection needle attached.

This will reduce the potential for contamination, infection, and leakage while also ensuring dosing accuracy.

Always use a new needle for each injection to prevent contamination.

: 285/00 Effective Date: 19/08/2025

Page 2 of 5

Section 8: Exposure Controls/Personal Protection

Avoid all unnecessary exposure. Personal protection

Appropriate engineering controls Work must be done with effective mechanical ventilation. There must be

access to running water and eve wash.

Individual protection measures. personal such as protective

equipment

Refer to applicable national standards and regulations in the selection and

use of personal protective equipment (PPE).

Hands Polyvinylchloride/ Nitrile rubber gloves

Eyes Wear safety glasses or goggles if eye contact is possible.

Skin Impervious protective clothing is recommended if skin contact with drug

products is possible and for bulk processing operations.

Respiratory protection Type A Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 &

149:2001, ANSI Z88 or national equivalent)

Section 9: Physical and Chemical Properties

HOW SUPPLIED Liraglutide Injection: 18 mg/3 mL (6 mg/mL) clear, colorless solution in a

pre-filled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or

1.8 mg is available in the following package sizes: 2 x Liraglutide Injection Pen NDC 70748-346-02 3 x Liraglutide Injection Pen NDC 70748-346-03

Section 10: Stability and Reactivity

Reactivity Not reactive under normal use and conditions. Avoid reaction with oxidizing

Chemical stability Product is considered stable

The product is considered stable. Hazardous polymerization will not occur.

None known. Possibility of hazardous reactions

Incompatible materials Keep away from strong oxidizers, excessive heat and sunlight.

Hazardous decomposition products No known hazardous decomposition products.

Section 11: Toxicological Information

Acute toxicity: Single dose studies were performed in mice and rats in standard design studies and in monkeys in a maximum tolerated dose (MTD) study. A single dose of 10 mg/kg was generally well tolerated by mice and rats without mortality. In monkeys, a single SC administration of 5 mg/kg was well tolerated without mortality. The observed reductions in body weight and food consumption can be regarded as pharmacologically mediated.

Chemical Name	Oral LD50.	Dermal LD50	Inhalation LC50	Intravenous LD50
Liraglutide	-	-	-	-
Phenol	317 mg/kg[2] (Rat)	850 mg/kg[2] (rabbit)	0.177 mg/L4h[2] (mouse)	-

Information on toxicological effects

Acute toxicity:

· Primary irritant effect:

· On the skin: There is sufficient evidence to classify this material as skin corrosive or irritating.

SDS : 285/00 Page 3 of 5

- · On the eye: Based on available data, the classification criteria are not met.
- Sensitization: No sensitizing effects known.
- · Additional toxicological information:
- · Interactive effects No interactive effects between components are known.

Carcinogenic categories

- · IARC (International Agency for Research on Cancer) Substance is not listed.
- · NTP (National Toxicology Program) Substance is not listed.
- · OSHA-Ca (Occupational Safety & Health Administration) Substance is not listed.
- · NIOSH (National Institute for Occupational Safety and Health) Substance is not listed.
- · Alternative sources for toxicological information NA

Section 12: Ecological Information

Toxicity

· Aquatic toxicity: No further relevant information available.

· Persistence and degradability

Ingredient Persistence: Water/Soil Persistence: Air

Phenol LOW (Half-life = 10 days) LOW (Half-life = 0.95 days

· Bio accumulative potential

Ingredient Bioaccumulation
Phenol LOW (BCF = 17.5)

· Mobility in soil

Ingredient Mobility

Phenol LOW (Log KOC = 268)

• Results of PBT and vPvB assessment

• **PBT**: Not applicable.

· vPvB: Not applicable.

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal, state, and local environmental regulations.

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated

IMDG Proper shipping Name:N/AIMDG UN/ID No:N/AIMDG Hazard Class:N/AIMDG Flash Point:N/AIMDG Label:N/A

DOT - Not Regulated

DOT Proper shipping Name:N/ADOT UN/ID No:N/ADOT Hazard Class:N/ADOT Flash Point:N/ADOT Packing Group:N/ADOT Label:N/A

SDS : 285/00 Page 4 of 5

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.

SDS : 285/00 Page 5 of 5